Jove
Visualize
Contact Us
JoVE
x logofacebook logolinkedin logoyoutube logo
ABOUT JoVE
OverviewLeadershipBlogJoVE Help Center
AUTHORS
Publishing ProcessEditorial BoardScope & PoliciesPeer ReviewFAQSubmit
LIBRARIANS
TestimonialsSubscriptionsAccessResourcesLibrary Advisory BoardFAQ
RESEARCH
JoVE JournalMethods CollectionsJoVE Encyclopedia of ExperimentsArchive
EDUCATION
JoVE CoreJoVE BusinessJoVE Science EducationJoVE Lab ManualFaculty Resource CenterFaculty Site
Terms & Conditions of Use
Privacy Policy
Policies

Filters

Gregory D Huhn

Showing results (21-30 of 31) with videos related to

Pageof 4
Sort By:
BMC Infectious Diseases|April 18, 2015
A matched cross-sectional study of the association between circulating tissue factor activity, immune activation and advanced liver fibrosis in hepatitis C infectionAimee C Hodowanec, Rebecca D Lee, Kirsten E Brady, et al.
Environmental Health Perspectives|May 4, 2005
Two outbreaks of occupationally acquired histoplasmosis: more than workers at riskGregory D Huhn, Connie Austin, Mark Carr, et al.
Journal of Acquired Immune Deficiency Syndromes (1999)|October 19, 2016
A Randomized, Open-Label Trial to Evaluate Switching to Elvitegravir/Cobicistat/Emtricitabine/Tenofovir Alafenamide Plus Darunavir in Treatment-Experienced HIV-1-Infected AdultsGregory D Huhn, Pablo Tebas, Joel Gallant, et al.
Antiviral Therapy|November 2, 2018
Daclatasvir and sofosbuvir with ribavirin for 24 weeks in chronic hepatitis C genotype-3-infected patients with cirrhosis: a Phase III study (ALLY-3C)Fred Poordad, Mitchell L Shiffman, Wayne Ghesquiere, et al.
AIDS Research and Therapy|December 16, 2010
Early development of non-hodgkin lymphoma following initiation of newer class antiretroviral therapy among HIV-infected patients - implications for immune reconstitutionGregory D Huhn, Sheila Badri, Sonia Vibhakar, et al.
The American Journal of Tropical Medicine and Hygiene|June 21, 2005
The emergence of west nile virus during a large outbreak in Illinois in 2002Gregory D Huhn, Connie Austin, Carl Langkop, et al.
AIDS Research and Therapy|August 30, 2019
Darunavir/cobicistat/emtricitabine/tenofovir alafenamide in treatment-experienced, virologically suppressed patients with HIV-1: subgroup analyses of the phase 3 EMERALD studyGregory D Huhn, Joseph J Eron, Pierre-Marie Girard, et al.
Plos One|February 14, 2020
Real-world efficacy of direct acting antiviral therapies in patients with HIV/HCVSonia Vibhakar Patel, Dushyantha T Jayaweera, Keri N Althoff, et al.
The Journal of Antimicrobial Chemotherapy|May 17, 2019
Pharmacokinetics of tenofovir monoester and association with intracellular tenofovir diphosphate following single-dose tenofovir disoproxil fumarateKristina M Brooks, Mustafa E Ibrahim, Jose R Castillo-Mancilla, et al.
Plos One|January 30, 2020
HIV/HCV therapy with ledipasvir/sofosbuvir after randomized switch to emtricitabine-tenofovir alafenamide-based single-tablet regimensGregory D Huhn, Moti Ramgopal, Mamta K Jain, et al.
Pageof 4

Showing results (21-30 of 31) with videos related to

Sort By:
Pageof 4
BMC Infectious Diseases|April 18, 2015
A matched cross-sectional study of the association between circulating tissue factor activity, immune activation and advanced liver fibrosis in hepatitis C infectionAimee C Hodowanec, Rebecca D Lee, Kirsten E Brady, et al.
Environmental Health Perspectives|May 4, 2005
Two outbreaks of occupationally acquired histoplasmosis: more than workers at riskGregory D Huhn, Connie Austin, Mark Carr, et al.
Journal of Acquired Immune Deficiency Syndromes (1999)|October 19, 2016
A Randomized, Open-Label Trial to Evaluate Switching to Elvitegravir/Cobicistat/Emtricitabine/Tenofovir Alafenamide Plus Darunavir in Treatment-Experienced HIV-1-Infected AdultsGregory D Huhn, Pablo Tebas, Joel Gallant, et al.
Antiviral Therapy|November 2, 2018
Daclatasvir and sofosbuvir with ribavirin for 24 weeks in chronic hepatitis C genotype-3-infected patients with cirrhosis: a Phase III study (ALLY-3C)Fred Poordad, Mitchell L Shiffman, Wayne Ghesquiere, et al.
AIDS Research and Therapy|December 16, 2010
Early development of non-hodgkin lymphoma following initiation of newer class antiretroviral therapy among HIV-infected patients - implications for immune reconstitutionGregory D Huhn, Sheila Badri, Sonia Vibhakar, et al.
The American Journal of Tropical Medicine and Hygiene|June 21, 2005
The emergence of west nile virus during a large outbreak in Illinois in 2002Gregory D Huhn, Connie Austin, Carl Langkop, et al.
AIDS Research and Therapy|August 30, 2019
Darunavir/cobicistat/emtricitabine/tenofovir alafenamide in treatment-experienced, virologically suppressed patients with HIV-1: subgroup analyses of the phase 3 EMERALD studyGregory D Huhn, Joseph J Eron, Pierre-Marie Girard, et al.
Plos One|February 14, 2020
Real-world efficacy of direct acting antiviral therapies in patients with HIV/HCVSonia Vibhakar Patel, Dushyantha T Jayaweera, Keri N Althoff, et al.
The Journal of Antimicrobial Chemotherapy|May 17, 2019
Pharmacokinetics of tenofovir monoester and association with intracellular tenofovir diphosphate following single-dose tenofovir disoproxil fumarateKristina M Brooks, Mustafa E Ibrahim, Jose R Castillo-Mancilla, et al.
Plos One|January 30, 2020
HIV/HCV therapy with ledipasvir/sofosbuvir after randomized switch to emtricitabine-tenofovir alafenamide-based single-tablet regimensGregory D Huhn, Moti Ramgopal, Mamta K Jain, et al.
Pageof 4